The effect of evolocumab alone and in combination with atorvastatin on atherosclerosis progression and TLRs expression

Evolocumab, a PCSK-9 inhibitor, is known for its ability to reduce low-density lipoprotein cholesterol (LDL-C). This study aimed to investigate the effects of evolocumab, alone or in combination with atorvastatin, on the progression of atherosclerosis. Fifty male domestic rabbits were randomly assig...

Descripción completa

Detalles Bibliográficos
Autores principales: Saud, Ali, Ali, Nabeel, Gali, Fadhil, Qassam, Heider, Hadi, Najah Rayish
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Carol Davila University Press 2023
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10375357/
https://www.ncbi.nlm.nih.gov/pubmed/37520489
http://dx.doi.org/10.25122/jml-2021-0210

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10375357/
https://www.ncbi.nlm.nih.gov/pubmed/37520489
http://dx.doi.org/10.25122/jml-2021-0210

Ejemplares similares